在肝细胞癌中对CDK20抑制剂进行量子化学优化和残留特异性稳定
Ahmed I Foudah1, Mohammed H Alqarni1, Tariq M Aljarba1
1Department of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, 11942, Al Kharj, Saudi Arabia.
Molecular diversity
|September 10, 2025
概括
研究人员确定了一种新型化合物153295720,作为循环素依赖激酶20 (CDK20) 的强有力的抑制剂. 这一发现提供了一个有希望的策略,通过稳定关键的CDK20残留物来准肝细胞癌 (HCC).
科学领域:
- 在瘤学瘤学.
- 生物化学 生物化学
- 计算化学计算化学
背景情况:
- 循环素依赖激酶20 (CDK20/CCRK) 与肝细胞癌 (HCC) 的进展有关.
- 在HCC中,CDK20调节β-catenin信号传递和细胞增殖.
- 目前缺乏对CDK20的选择性小分子抑制剂.
研究的目的:
- 确定新的CDK20.20小分子抑制剂.
- 通过计算选和验证潜在的CDK20抑制剂.
- 为在HCC中实验性向CDK20提供基础.
主要方法:
- 在PubChem数据库中进行虚拟选,寻找与已知的CDK20抑制剂相似的化合物.
- 使用MTiOpenScreen进行基于结构的虚拟选,并与AlphaFold预测的CDK20.20进行对接.
- 通过密度函数理论 (B3LYP/cc-pVDZ) 的几何优化.
- 分子动力学 (MD) 模拟 (500 ns) 和MM/GBSA约束能计算.
- 自由能源景观分析.
主要成果:
- 化合物153295720显示出与CDK20的结合亲和力最高 (-11.8 kcal/mol).
- 153295720与活性部位残留物Met84,Lys33,Ala131和Asp145.5形成了关键相互作用.
- MD模拟证实了153295720-CDK20复合物的稳定性,波动最小.
- 对于153295720.20,MM/GBSA分析给出了最有利的结合能 (-69.09 ± 8.29 kcal/mol) 的结果.
- 与153295720相比,参考化合物显示出更大的形状漂移.
结论:
- 化合物153295720是一种结构和动态上优异的CDK20抑制剂.
- 这种抑制剂有效地稳定了CDK20的关键催化残留物.
- 这些发现支持153295720对HCC治疗的潜力,并指导未来的实验验证.
更多相关视频
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.4K
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
5.9K
相关概念视频
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
M-Cdk Drives Transition Into Mitosis
6.2K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
